3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Urinary Bladder Neoplasms
7
Non-Muscle Invasive Bladder Neoplasms
5
Recurrence
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Melanoma
1
Carcinoma in Situ
1
Interventions
pembrolizumab
180
Cisplatin
44
Paclitaxel
41
Carboplatin
41
lenvatinib
31
Docetaxel
22
Pemetrexed
20
Fluorouracil
19
Capecitabine
16
Gemcitabine
15
Saline Solution
13
Oxaliplatin
13
Albumin-Bound Paclitaxel
10
epacadostat
9
130-nm albumin-bound paclitaxel
9
Leucovorin
8
Cetuximab
8
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
belzutifan
5
Dexamethasone
5
enzalutamide
4
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
BCG Vaccine
×
Clear all
NCT03711032
2026-05-01
MK-3475-676
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
1,397 enrolled